I've been following the progress of the Invest in ME Research Centre of Excellence projects since the charity published the proposal and announced it at their international London conference in May 2010. This is just a summary for anyone who wasn't around at the time or able to follow over the years (otherwise please skip post).
Norwich Research Park is the hub at the centre, but the project radiates out nationally and internationally, and so far includes UCL, where the B-cell studies prerequisite to the UK trial, led by Jo Cambridge, have been underway since 2014; and Oxford with Invest in ME Research Advisory Board member Angela Vincent.
Collaboration in Europe includes Norway (the Phase II trial was presented at the 2011 Invest in ME Conference prior to publication), Germany, Spain, Sweden (Jonathan Edwards will know if there are more), facilitated by the formation of the European ME Research Group, a project of the European ME Alliance.
International collaboration includes the various researchers involved in the international Invest in ME Conference and Biomedical Research into ME Colloquium, but a fine example is the three months spent by medical student Navena Navaneetharaja (now a qualified medical doctor) from the Norwich team with Maureen Hanson at her Cornell lab.
The Invest in ME Research Centre of Excellence for ME translational biomedical research strategy began with the gut. This was planned from the outset in 2010 and the work began in October 2013 with a 3-year foundation study investigating the role of leaky gut in ME (ME/CFS for research purposes) leading into the next phases of that research. Norfolk PCT (Primary Care Trust) had agreed to fund a clinical specialist for examinations.
The NHS reforms following the 2010 general election set that back as the PCTs were disbanded and the negotiations had to begin again within the new structures and personnel. The research was enabled to get underway by using samples from patients under the care of Amolak Bansal, clinical lead of the Surrey CFS Service. This has since included patients with severe ME by means of samples taken at home visits.
Also in June 2013, following their annual international London conference events, Invest in ME Research announced the plan for a UK trial in collaboration with UCL, with Jonathan Edwards advising on the trial, which he recommended begin with a preliminary study of B-cells in ME patients. This began in 2014 and included patients of Amolak Bansal (Surrey) and Saul Berkovitz (London). This work has also been of value to the Phase III Norwegian trial. The paper on the initial study has been published and the work is currently ongoing.
Please anyone shout if you'd like links etc.